Forsythoside B, the active component of Frosythiae fructuse water extract, alleviates Streptococcus pneumoniae virulence by targeting pneumolysin.

IF 3.2 3区生物学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Journal of Applied Microbiology Pub Date : 2024-10-03 DOI:10.1093/jambio/lxae251

Zhongtian Wang, Yingying Sun, Kuan Gu, Yue Tong, Huanyu Liu, Lei Wang, Tianhui Tan, Fushuang Yang, Xiaoting Ren, Lizhong Ding, Liping Sun, Lie Wang

{"title":"Forsythoside B, the active component of Frosythiae fructuse water extract, alleviates Streptococcus pneumoniae virulence by targeting pneumolysin.","authors":"Zhongtian Wang, Yingying Sun, Kuan Gu, Yue Tong, Huanyu Liu, Lei Wang, Tianhui Tan, Fushuang Yang, Xiaoting Ren, Lizhong Ding, Liping Sun, Lie Wang","doi":"10.1093/jambio/lxae251","DOIUrl":null,"url":null,"abstract":"Aims: To explore the therapeutic potential of Forsythoside B in treating Streptococcus pneumoniae (S. pneumoniae) infections, focusing on its ability to inhibit pneumolysin activity and protect cells from damage.Methods and results: Hemolysis tests were used to evaluate Forsythoside B's inhibitory effect on pneumolysin activity, while growth curve analysis assessed its impact on S. pneumoniae growth. Western blotting and oligomerization analysis were conducted to examine its influence on pneumolysin oligomerization. Cytotoxicity assays, including LDH release and live/dead cell staining, evaluated the protective effects of Forsythoside B against pneumolysin-induced damage in A549 cells. Additionally, a mouse model was employed to test the effects on survival rates, lung bacterial load, and inflammation. The results showed that Forsythoside B significantly inhibited pneumolysin activity, reduced its oligomerization, and protected A549 cells from damage without affecting bacterial growth. In the mouse model, it improved survival rates and reduced lung inflammation, indicating its potential as a therapeutic agent against S. pneumoniae infections.Conclusions: Forsythoside B shows potential as a therapeutic agent for treating pneumonia, particularly in infections caused by S. pneumoniae.","PeriodicalId":15036,"journal":{"name":"Journal of Applied Microbiology","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Applied Microbiology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1093/jambio/lxae251","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: To explore the therapeutic potential of Forsythoside B in treating Streptococcus pneumoniae (S. pneumoniae) infections, focusing on its ability to inhibit pneumolysin activity and protect cells from damage.

Methods and results: Hemolysis tests were used to evaluate Forsythoside B's inhibitory effect on pneumolysin activity, while growth curve analysis assessed its impact on S. pneumoniae growth. Western blotting and oligomerization analysis were conducted to examine its influence on pneumolysin oligomerization. Cytotoxicity assays, including LDH release and live/dead cell staining, evaluated the protective effects of Forsythoside B against pneumolysin-induced damage in A549 cells. Additionally, a mouse model was employed to test the effects on survival rates, lung bacterial load, and inflammation. The results showed that Forsythoside B significantly inhibited pneumolysin activity, reduced its oligomerization, and protected A549 cells from damage without affecting bacterial growth. In the mouse model, it improved survival rates and reduced lung inflammation, indicating its potential as a therapeutic agent against S. pneumoniae infections.

Conclusions: Forsythoside B shows potential as a therapeutic agent for treating pneumonia, particularly in infections caused by S. pneumoniae.

查看原文本刊更多论文

连翘水提取物的活性成分连翘苷 B 可通过靶向肺炎溶素减轻肺炎链球菌的毒力。

目的：探讨连翘苷 B 治疗肺炎链球菌感染的潜力，重点研究其抑制肺炎溶菌酶活性和保护细胞免受损伤的能力：溶血试验用于评估连翘皂苷 B 对肺炎溶菌酶活性的抑制作用，而生长曲线分析则评估了连翘皂苷 B 对肺炎链球菌生长的影响。还进行了 Western 印迹和寡聚分析，以研究连翘苷 B 对肺炎溶素寡聚的影响。细胞毒性试验（包括 LDH 释放和活/死细胞染色）评估了连翘苷 B 对肺炎双球菌诱导的 A549 细胞损伤的保护作用。此外，还利用小鼠模型测试了连翘苷 B 对存活率、肺部细菌负荷和炎症的影响。结果表明，连翘皂苷 B 能明显抑制肺溶素的活性，减少其低聚作用，保护 A549 细胞免受损伤，而不影响细菌的生长。在小鼠模型中，连翘苷 B 提高了存活率，减轻了肺部炎症，显示了其作为肺炎链球菌感染治疗剂的潜力：结论：连翘苷 B 具有治疗肺炎的潜力，尤其是在肺炎双球菌感染中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Applied Microbiology 生物-生物工程与应用微生物

CiteScore

7.30

自引率

2.50%

发文量

427

审稿时长

2.7 months

期刊介绍： Journal of & Letters in Applied Microbiology are two of the flagship research journals of the Society for Applied Microbiology (SfAM). For more than 75 years they have been publishing top quality research and reviews in the broad field of applied microbiology. The journals are provided to all SfAM members as well as having a global online readership totalling more than 500,000 downloads per year in more than 200 countries. Submitting authors can expect fast decision and publication times, averaging 33 days to first decision and 34 days from acceptance to online publication. There are no page charges.